Association between the level of circulating adiponectin and prediabetes: A meta-analysis

Huasheng Lai†, Nie Lin†, Zhenzhen Xing†, Huanhuan Weng†, Hua Zhang*
Department of Endocrinology, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Keywords
Adiponectin, Meta-analysis, Prediabetes

*Correspondence
Hua Zhang
Tel.: +86-13711170617
Fax: +86-20-6164-3521
E-mail address: jimzhua@gmail.com

J Diabetes Invest 2015; 6: 416–429
doi: 10.1111/jdi.12321

ABSTRACT
Aims/Introduction: Adiponectin has been proposed to have an essential role in the regulation of insulin sensitivity and metabolism, but previous studies on levels of adiponectin in prediabetes remain inconsistent. The present study aimed to assess the differences of adiponectin levels between prediabetes patients and healthy controls by carrying out a meta-analysis.

Materials and Methods: We carried out a systematic literature search of PubMed, EMBASE, and other databases for case–control studies and cohort studies measuring adiponectin levels in serum or plasma from prediabetes patients and healthy controls. The pooled weighted mean difference (WMD) and 95% confidence interval (CI) were used to estimate the association between adiponectin levels and prediabetes.

Results: Three cohort studies and 15 case–control studies with a total of 41,841 participants were included in the meta-analysis. The results showed that circulating adiponectin levels in prediabetes patients were significantly lower than that of healthy controls (WMD –1.694 μg/mL; 95% CI –2.151, –1.237; P < 0.001). Subgroup analysis showed more significant differences between prediabetes patients and healthy controls when the ratio of the homeostatic model assessment of insulin resistance was >2.12 (WMD –2.95 μg/mL; 95% CI –4.103, –1.806; P < 0.001) and average age was >60 years (WMD –2.20 μg/mL; 95% CI –3.207, –1.201; P < 0.001). Additionally, WMD in adiponectin showed a trend of direct correlation in subgroups of homeostatic model assessment of insulin resistance ratio, body mass index and age.

Conclusions: The present meta-analysis supports adiponectin levels in prediabetes patients being lower than that of healthy controls, indicating that the level of circulating adiponectin decreases before the onset of diabetes.

INTRODUCTION
Type 2 diabetes is a complex metabolic disease, the prevalence of which has tripled in the past 30 years, and diabetes is predicted to cover more than 320 million people by 2025. Before the occurrence of diabetes, there is an intermediate stage called prediabetes, which is generally defined as impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both. According to the report of the American Diabetes Association, IGT is defined as fasting plasma glucose <7.0 mmol/L and 2-h plasma glucose on the 75-g oral glucose tolerance test between 7.8 and 11.0 mmol/L, and impaired fasting glucose (IFG) is defined as plasma glucose concentration of between 6.1 and 6.9 mmol/L. There are currently 79 million people in the USA with prediabetes. Approximately 30% of those with prediabetes will progress to type 2 diabetes within a decade. Type 2 diabetes is associated with increased mortality, mostly as a result of cardiovascular causes, compared with populations who have normal glucose tolerance. Fortunately, large numbers of studies have shown that prediabetes can be reversed by changing lifestyle and pharmacological interventions. Thus, it is of great importance to diagnose prediabetes at an early stage, and carry out effective interventions before cardiovascular events emerge.

Adiponectin, a 30-kDa complement C1-related protein, is the most abundant secreted protein expressed in adipose
tissue, and plays a crucial role in the regulation of insulin sensitivity and glucose metabolism. Lower circulating adiponectin levels is associated with obesity and negatively correlated with insulin resistance. In addition, it has been proposed that adiponectin exerts antidiabetic, anti-atherogenic and anti-inflammatory activities in metabolic diseases. Therefore, circulating adiponectin levels might represent a significant clinical diagnostic biomarker for the future development of prediabetes. However, its role in the development of diabetes remains unclear.

Understanding the association between circulating adiponectin and prediabetes could provide useful information on the disease, and might help impose a stricter follow up and possibly an early treatment initiation, thus preventing the progression to diabetes. In addition, given the fact that low adiponectin levels could serve as a risk factor for cardiovascular diseases in prediabetes, adiponectin levels in prediabetes might help monitor the prognosis of cardiovascular diseases. Furthermore, knowing that adiponectin exerts antidiabetic, anti-atherogenic and anti-inflammatory activities in metabolic diseases, pharmacological adiponectin treatments could be applied in prediabetes. However, currently, no study has systematically summarized the existing evidence to explore the certain association between the level of adiponectin and prediabetes.

To investigate adiponectin levels in patients with prediabetes, a systematic review of all studies reporting total adiponectin levels in patients with prediabetes and a meta-analysis of the best available evidence were carried out.

**MATERIALS AND METHODS**

**Search Strategy**

Three investigators identified articles through a comprehensive systematic electronic search of PubMed, EMBASE and other databases up to 30 April 2014 using the following MeSH terms: ‘prediabetes,’ ‘impaired glucose tolerance,’ ‘impaired fasting glucose,’ ‘IGT,’ ‘IFG’ and ‘adiponectin.’ Also, reference lists of relevant articles were screened for eligibility. In addition, we wrote to authors to ask for unpublished or more complete information. No language restriction was applied for searching. Any discrepancy was resolved by consultation to reach a consensus with a fourth investigator. Our meta-analysis was carried out according to the Meta-analysis of Observational Studies in Epidemiology guidelines.

**Inclusion Criteria**

All of the included studies were required to meet the following inclusion criteria:

1. Case–control studies or cohort studies design.
2. Studies should report serum or plasma adiponectin levels on prediabetes patients (diagnosed consistently by either American Diabetes Association [ADA] or World Health Organization [WHO] criteria) compared with healthy controls.
3. Data of total adiponectin mean and standard deviation (SD), or sufficient data to estimate adiponectin mean and SD should be provided.
4. No medications known to influence circulating adiponectin were used.

We excluded literature reviews, letters to the editor, cross-sectional studies, randomized controlled trials, studies of animals or cell lines, studies of genetic variation in adiponectin-related genes and studies of gestational diabetes. We also excluded studies on populations with diseases other than prediabetes. Studies of medication treatment and studies classifying prediabetes into diabetes were also excluded.

**Data Extraction**

A standard data extraction form was used by three investigators independently to collect the information from all suitable studies. Any disagreements were resolved by discussion during a consensus meeting with a fourth investigator. The following information were extracted from each eligible study: first author’s name, year of publication, region of studies, type of study design, sample size, methods of adiponectin measurement, the type of blood sample, adiponectin levels of cases and controls (mean and SD), the number of males and females, the age of cases and controls (mean and SD), the body mass index (BMI) of cases and controls (mean and SD), homeostasis model assessment of insulin resistance ratio (HOMA-IR ratio) and predefined criteria (a modification of the Newcastle–Ottawa Scale [NOS]). To retrieve the missing data, we also contacted the authors of the primary studies.

**Quality Evaluation of Literature**

Quality evaluation of the studies was carried out independently by three viewers according to a modification of the NOS. The NOS tool contains nine items, and scores ranged from 0 to 9. The main criteria include: (i) the selection of cases and controls; (ii) the comparability; and (iii) the exposure.

**Statistical Analysis**

The mean, SD or standard error (SE) on plasma or serum adiponectin levels were extracted in all included studies. The meta-analysis was based on sufficient information directly providing the mean and SD. Weighted mean differences (WMDs) along with the corresponding 95% confidence intervals (CIs) in adiponectin levels of all suitable cases and controls were estimated using a fixed-effects model. If there was significant heterogeneity, we used a random effects model. First, heterogeneity tests were carried out by means of Cochran’s Q test and $I^2$ statistic to evaluate statistical heterogeneity among studies. Statistically significant heterogeneity was considered when the P-value was <0.1 and the $I^2$ value was more than 50%. Subsequently, the following tests were carried out to identify the sources of heterogeneity between the results of different studies. Subgroup analysis was carried out to investigate influencing factors. Many
subgroups were analyzed according to geographic region, sample size, age, BMI, HOMA-IR ratio, blood sample, method, quality score and sex. Restricted maximum likelihood-based random effects meta-regression analysis was carried out to evaluate the aforementioned potential heterogeneity factors. Univariate meta-regression analysis was carried out first, after which the variables that were significant at the 0.1 level were entered into the multivariable model. To identify potentially influential studies, sensitivity analysis was also carried out to examine whether the effect estimate was robust by repeating the random effect meta-analysis after omitting one study at a time. Furthermore, cumulative meta-analysis was carried out to evaluate the evolution of the combined estimates over time according to the ascending date of publication. Finally, the possibility of publication bias was assessed by Begg’s funnel plots and Egger’s test.

All statistical analyses were carried out using Stata version 12.0 (StataCorp LP, College Station, TX, USA). A two-sided $P$-value $<0.05$ was considered statistically significant.

**RESULTS**

**Literature Search Results**

A flow chart shows our process of study selection (Figure 1). A total of 1,942 potentially relevant articles were identified in PubMed, EMBASE and other databases, and 278 duplicates were removed. A total of 1,664 potentially relevant articles were evaluated. Out of these, 1,550 were excluded according to titles and abstracts, 626 nothing with prediabetes and adiponectin, 351 animals, cell lines and gene researches, 271 review, meta-analysis, and clinical trials, 237 with more than one disease, 65 gestational diabetes or pregnancy, 114 were evaluated in detail. Out of these, 96 were excluded with reasons, 64 no specific classification, 23 cross-sectional studies, 7 no sufficient information, 1 sample size less than 20, 1 no full text. A total of 18 studies were included in the meta-analysis.

**Figure 1** | Flow chart of study selection. After careful discussion among the investigators, a total of 18 studies were included to carry out the meta-analysis.
evaluated according to their titles and abstracts: 626 studies had no relationship with prediabetes or adiponectin levels; 351 studies were focused on animals, cell lines and genes; 271 studies belonged to reviews, meta-analyses and clinical trials; 237 studies discussed prediabetes along with another disease; and 65 studies specifically researched gestational diabetes. Subsequently, 114 articles were evaluated in detail: 64 studies had not referred to adiponectin; 58 studies did not extract or calculate mean and SD; one study had no full text to extract useful data; and one study had <10 samples in all groups. Finally, 18 available studies were included in our meta-analysis.

### Table 1 | Characteristics of the included studies of circulating adiponectin and prediabetes

| Study year | Region | Study design | Blood sample | Method | Sample size | Sex | Age (years) | BMI (kg/m²) | Adiponectin (µg/mL) | HOMA-IR | NOS |
|------------|--------|--------------|--------------|--------|-------------|-----|-------------|--------------|-------------------|---------|-----|
| Christian (2003) | Asia | Case-control | Plasma | ELISA | 79 | 25 | 76 | 28 | 27 ± 6 | 31 ± 8 | >30 | 7.5 ± 2.7 | 6.1 ± 2.0 | NR | 8 |
| Nobert (2003) | Asia | Case-control | Plasma | ELISA | 94 | 33 | 93 | 34 | 28 ± 7 | 33 ± 8 | NA | 7.05 ± 2.70 | 5.44 ± 2.23 | NR | 7 |
| Alice (2003) | USA | Case-control | Plasma | RA | 108 | 18 | 0 | 126 | 46.7 ± 1.5 | 56.1 ± 1.8 | 25-30 | 6.18 ± 0.67 | 2.78 ± 0.78 | NR | 6 |
| Chamkuttan (2002) | Asia | Cohort | Plasma | RA | 50 | 32 | 73 | 68 | 45.7 ± 11.3 | 44.2 ± 5.3 | 25-30 | 14.9 ± 5.9 | 15.2 ± 7.5 | NR | 7 |
| Awame (2003) | USA | Case-control | Serum | ELISA | 19 | 8 | 4 | 23 | 4.1 ± 7.86 | 51.0 ± 9.3 | >30 | 9.61 ± 5.09 | 10.42 ± 6.89 | 1.71 | 8 |
| Munehide (2007) | Asia | Case-control | Serum | Others | 23 | 5 | NR | NR | 4.97 ± 10.2 | 43.2 ± 19.8 | 25-30 | 5.8 ± 2.2 | 6.8 ± 3.3 | NR | 6 |
| Carl (2008) | Europe | Case-control | Serum | ELISA | 97 | 201 | 0 | 298 | 64 | 64 | 25-30 | 15.1 ± 63 | 12.9 ± 66 | 1.34 | 6 |
| Sang (2007) | Asia | Case-control | Plasma | RA | 36 | 49 | 35 | 50 | 47.5 ± 13.6 | 53.0 ± 9.7 | <25 | 5.20 ± 2.87 | 4.00 ± 3.64 | 1.39 | 5 |
| Natsuki (2009) | Asia | Case-control | Serum | ELISA | 11 | 9 | 20 | 0 | 410 ± 12.0 | 493 ± 12.3 | <25 | 9.2 ± 4.3 | 7.1 ± 2.2 | 2.25 |
| Kasi (2010) | Europe | Case-control | Serum | ELISA | 18 | 20 | 0 | 38 | 55 ± 9 | 61 ± 6 | >30 | 11.9 ± 44 | 13 ± 58 | 1.58 | 6 |
| Stefan (2010) | Europe | Case-control | Plasma | ELISA | 13 | 13 | 26 | 0 | 506 ± 10 | 500 ± 13 | >30 | 5.2 ± 2.4 | 3.2 ± 0.9 | 1.78 | 6 |
| Anke (2010) | Europe | Case-control | Serum | ELISA | 43 | 35 | 33 | 43 | 613 ± 93 | 619 ± 123 | >30 | 8.8 ± 4.7 | 7.2 ± 4.7 | 1.90 |
| IFG (2009) | Asia | Case-control | Serum | ELISA | 43 | 45 | 37 | 51 | 613 ± 93 | 633 ± 8.8 | >30 | 8.8 ± 4.7 | 6.2 ± 3.2 | 2.59 |
| Kasi (2010) | Europe | Case-control | Serum | Others | 224 | 52 | 360 | 0 | 403 ± 90 | 424 ± 9.4 | 25-30 | 5.72 ± 2.94 | 4.80 ± 2.10 | NR | 8 |
| Wolfson (2011) | Asia | Case-control | Plasma | ELISA | 55 | 24 | 33 | 46 | 557 ± 95 | 588 ± 96 | >30 | 12.60 ± 7.24 | 7.57 ± 4.19 | 2.57 | 6 |
| Webb (2012) | Asia | Case-control | Serum | Others | 79 | 40 | 76 | 82 | 52.1 ± 98 | 55.1 ± 11.7 | 25-30 | 13.6 ± 3.23 | 12.40 ± 3.85 | 1.56 | 7 |
| Sun (2013) | Asia | Cohort | Serum | ELISA | 21,766 | 4,101 | 25,867 | 0 | 415 ± 9.1 | 452 ± 9.3 | <25 | 66.6 ± 3.7 | 57.7 ± 3.3 | NR | 7 |
| Male | 13,098 | 1,048 | 14,138 | 0 | 409 ± 100 | 477 ± 112 | <25 | 105.5 ± 55 | 86.6 ± 5.0 | NR | 7 |
| Female | 8,668 | 3,053 | 11,739 | 0 | 446 ± 98 | 498 ± 112 | <25 | 112.0 ± 472 | 874 ± 349 | 2.84 | 6 |

**Study Characteristics**

The meta-analysis of 18 studies involved 41,841 participants: 5,879 individuals with prediabetes and 35,962 control subjects. Among them, three studies presented two subgroups of prediabetes, each subgroup had been independently compared with a control group. As a result, each of them was treated as an independent study. Therefore, a total of 21 studies were included in our final meta-analysis. The main characteristics of the 21 resulting studies were summarized in Table 1. The studies were published between 2001 and 2014, including three cohort studies and 15 case–control studies. Geographically, 14 studies were carried out in Asia, five in Europe.

Data presented as mean ± standard deviation. BMI, body mass index (calculated as weight in kg divided by height in m²); ELISA, enzyme-linked immunosorbent assay; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-IR ratio, mean values of homeostatic model assessment of insulin resistance prediabetes patients to controls in a single study; NR, not reported; NOS, Newcastle–Ottawa Scale; PD, prediabetes; RIA, radioimmunoassay.
and two in the USA. All studies compared individuals with prediabetes with control subjects, ranging from 20 to 25,867 in total sample size. Among 21 studies, four studies\textsuperscript{16–18,26} included only female participants, and five studies\textsuperscript{17,19,23,24} included only male participants. The mean BMI of participants in all studies ranged from 22.1 to 40.16 kg/m\textsuperscript{2}, and the mean age ranged from 27 to 64 years. There were nine studies without HOMA-IR results, and the mean HOMA-IR ratio in 12 studies ranged from 1.06 to 6.96. Total and HWM adiponectin levels were measured by enzyme-linked immunosorbent assay in 14 studies, whereas four studies used radioimmunoassay and three used other methods. Additionally, 13 studies used serum specimens to measure the adiponectin level, while the remaining studies used the plasma. Furthermore, 13 studies elucidated that no participant took medications that could affect the adiponectin level, whereas eight studies did not mention the medication records. The overall quality score of the involved studies averaged 6.6 on a scale of 0 to 9.

Data Synthesis
The random effects meta-analysis results showed that the adiponectin levels in prediabetes patients were significantly lower than healthy controls (WMD $-1.694$ μg/mL; 95% CI $-2.151$, $-1.237$; $P < 0.001$). However, significant heterogeneity in this meta-analysis was present ($I^2 = 89.9\%$, $P < 0.001$; Figure 2). Therefore, subgroup analysis should be carried out to explore the possible reasons for this heterogeneity.

Subgroup Analysis
Subgroup analysis was carried out to explore the sources of heterogeneity. Potential sources of heterogeneity were evaluated, including geographic region, sample size, age, HOMA-IR ratio, BMI, quality score, assay methods (Figure S1), the type of blood sample (Figure S2) and sex (Table 2). Almost all results of subgroup analysis showed that adiponectin levels in prediabetes patients were significantly lower than healthy controls, except in geographic region and sample size. As for geographic region, a significant decrease of adiponectin levels was observed between prediabetes patients and healthy controls in the included studies carried out in Asia (WMD $-1.412$ μg/mL; 95% CI $-1.770$, $-1.053$; $P < 0.001$) and Europe (WMD $-1.937$ μg/mL; 95% CI $-2.745$, $-1.128$; $P < 0.001$). However, it was not significantly different in adiponectin levels in the included studies carried out in the USA (WMD $-2.157$ μg/mL; 95% CI $-5.921$, 1.607; $P = 0.261$; Figure 3). For sample size, there was no significant difference in adiponectin levels between prediabetes patients and healthy controls in studies with sample sizes <50 (WMD $-1.144$ μg/mL; 95% CI $-2.475$, 0.187;...
Table 2 | Subgroup analysis of the included studies of circulating adiponectin and prediabetes

| Characteristic | No. participants | Random effects WMD (95% CI) | P-value | Heterogeneity |
|---------------|------------------|-----------------------------|---------|---------------|
| All studies   | 41,841           | -1.694 (-2.151, -1.237)     | <0.001  | 89.9          |
| Region        |                  |                             | <0.001  | 88.9          |
| Asia          | 41,160           | -1.412 (-1.770, -1.053)     | <0.001  | 72.8          |
| Europe        | 528              | -1.937 (-2.745, -1.128)     | <0.001  | 3.7           |
| USA           | 153              | -2.157 (-5.921, 1.607)      | 0.261   | 58.6          |
| Sample size   |                  |                             |         |               |
| <50           | 161              | -1.144 (-2.475, 0.187)      | 0.092   | 30.3          |
| 50–100        | 495              | -2.103 (-3.266, -0.941)     | <0.001  | 48.4          |
| >100          | 41,185           | -1.679 (-2.235, -1.122)     | <0.001  | 95.5          |
| Age (years)   |                  |                             |         |               |
| <50           | 40,947           | -1.571 (-2.135, -1.007)     | <0.001  | 93.9          |
| 50–60         | 347              | -1.715 (-3.016, -0.414)     | 0.010   | 62.2          |
| >60           | 464              | -2.204 (-3.207, -1.201)     | <0.001  | 0.0           |
| NR            | 83               | -2.461 (-4.619, -0.303)     | 0.025   |               |
| HOMA-IR ratio |                  |                             |         |               |
| <1.36         | 298              | -2.200 (-3.751, -0.649)     | 0.005   |               |
| 1.36–1.7      | 203              | -1.189 (-2.102, -0.276)     | 0.011   | 3.6           |
| 1.71–2.12     | 131              | -1.754 (-2.888, -0.621)     | 0.002   | 0.0           |
| >2.12         | 270              | -2.955 (-4.103, -1.806)     | <0.001  | 7.8           |
| NR            | 40,878           | -1.539 (-2.128, -0.951)     | <0.001  | 95.5          |
| BMI           |                  |                             |         |               |
| <25           | 40,262           | -1.394 (-1.846, -0.943)     | <0.001  | 88.9          |
| 25–30         | 1,012            | -1.587 (-2.834, -0.340)     | 0.013   | 87.4          |
| >30           | 440              | -1.894 (-2.932, -0.857)     | <0.001  | 49.1          |
| NR            | 127              | -1.610 (-2.546, -0.674)     | 0.001   |               |
| Quality score |                  |                             |         |               |
| <7            | 805              | -2.129 (-3.099, -1.158)     | <0.001  | 69.6          |
| ≥7            | 41,036           | -1.365 (-1.716, -1.015)     | <0.001  | 79.6          |
| Method        |                  |                             |         |               |
| ELISA         | 41,042           | -1.595 (-1.989, -1.202)     | <0.001  | 79.8          |
| RIA           | 376              | -2.001 (-3.622, -0.381)     | 0.015   | 79.3          |
| Others        | 423              | -1.051 (-1.655, -0.446)     | 0.001   | 0.0           |
| Blood sample  |                  |                             |         |               |
| Serum         | 41,129           | -1.374 (-1.754, -0.994)     | <0.001  | 77.9          |
| Plasma        | 712              | -2.130 (-3.103, -1.158)     | <0.001  | 81.0          |
| Sex           |                  |                             |         |               |
| Male          | 26,211           | -1.071 (-1.444, -0.698)     | <0.001  | 20.9          |
| Female        | 14,600           | -2.178 (-3.384, -0.971)     | <0.001  | 92.5          |

BMI, body mass index; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; HOMA-IR ratio, mean values of homeostatic model assessment of insulin resistance in prediabetes patients to controls in a single study; NR, not reported; RIA, radioimmunoassay; WMD, weight mean difference.

\( P = 0.092; \text{Figure S3}. \) All subgroup analysis still showed significant heterogeneity. Furthermore, for HOMA-IR ratio group (Figure 4), WMD in adiponectin showed a trend of a direct correlation except HOMA-IR ratio <1.36. Additionally, WMDs in adiponectin showed a trend of direct correlation in subgroups of BMI and age (Figures 5 and 6). Furthermore, as for sex, the decrease of adiponectin levels between prediabetes patients and healthy controls in female participants (WMD -2.178 µg/mL, 95% CI -3.384, -0.971; \( P < 0.001 \)) was more significant than that in male participants (WMD -1.071 µg/mL, 95% CI -1.444, -0.698; \( P < 0.001 \); Figure 7).

**Meta-Regression**

To further investigate the impact of the aforementioned characteristics on WMD in adiponectin, restricted maximum likelihood-based random effects meta-regression analyses were carried out (Table 3). WMD was used as the dependent variable. Geographic region, sample size, age, HOMA-IR ratio and BMI were
used as explanatory covariates. The result of univariate meta-regression analysis showed that geographic region could contribute significantly to the heterogeneity (Asia: 14 studies, \( P = 0.001 \); Europe: 5 studies, \( P = 0.053 \)). Additionally, sample size (21 studies, \( P = 0.398 \)), age (20 studies, \( P = 0.393 \)), HOMA-IR ratio (12 studies, \( P = 0.074 \)) and BMI (19 studies, \( P = 0.391 \)) cannot account for heterogeneity of the analysis.

Cumulative Meta-Analysis
The result of cumulative meta-analysis from the year 2001 by Christian et al.\(^\text{32}\) showed that the random effects pooled WMD was instable. However, a statistically significant effect was observed in the study by Sang et al.\(^\text{25}\) in 2007, and it changed little after that study, showing the stability of the result in the present meta-analysis.

Sensitivity Analysis and Publication Bias
A sensitivity analysis was carried out by omitting one study at a time. We used random effects to estimate and calculate the WMD for the remaining studies. The result showed that none of the individual studies dramatically influenced the effect of the meta-analysis when any one of the studies was excluded, showing that the results of the meta-analysis were stable and reliable (Figure S4). Publication bias was evaluated by Begg’s funnel plots and Egger’s tests (\( t = -1.42, P = 0.173 \). Figure 8). No publication bias was observed in the present meta-analysis.

DISCUSSION
The present meta-analysis of relevant studies suggested that adiponectin levels were significantly lower in patients with prediabetes compared with healthy controls (random-effects WMD \(-1.96\); 95% CI \(-2.15, -1.24\); \( I^2 = 89.9% \). Subgroup analysis showed more significant differences between prediabetes patients and healthy controls when the HOMA-IR ratio was >2.12 (WMD \(-2.95 \mu g/mL\); 95% CI \(-4.103, -1.806\); \( P < 0.001 \)) and mean age >60 years (WMD \(-2.20 \mu g/mL\); 95% CI \(-3.39, -0.91\); \( P < 0.001 \)).

Many studies have been shown to uncover the relationship between adiponectin and prediabetes. A meta-analysis published in Journal of the American Medical Association in 2009 with a total of 14,598 participants and 2,623 incident cases showed that lower adiponectin levels were associated with a higher incidence of insulin resistance and type 2 diabetes in
A cross-sectional, genetic epidemiology study in 2009 with 1,599 American Samoan adults suggested that adiponectin is an independent risk factor of type 2 diabetes, and might help distinguish those at higher risk of developing this disease. Furthermore, a most recent and up-to-date cohort study in 2014 carried out by Yamamoto Sin Japan suggested that higher levels of circulating adiponectin are associated with a lower risk of type 2 diabetes, and that adiponectin could confer a benefit in both persons with and without prediabetes. The same results were shown in other studies.

However, inconsistent results regarding this have been reported in another two studies. Using the adiponectin gene summary statistics genetic risk scores, Mente et al. found no evidence of an association between adiponectin-lowering alleles and insulin sensitivity, which do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. In addition, Hammana et al. found no alterations in adiponectin levels despite insulin resistance, glucose intolerance and subclinical chronic inflammation in cystic fibrosis patients. Thus, the relationship between adiponectin values and insulin resistance or inflammation is unclear as a result of other confounding diseases.

The insulin-sensitizing effect of adiponectin was summarized by three independent routes. First, in vitro studies have suggested that both isoforms of adiponectin receptor (AdipoR1 and AdipoR2) can increase adenosine monophosphate-activated protein kinase phosphorylation and peroxisome proliferator-activated receptor-α activity by adiponectin binding, thus increasing fatty acid oxidation and glucose uptake. The mechanism is related to phosphorylation of acetyl coenzyme A carboxylase, fatty-acid oxidation, glucose uptake and lactate production in myocytes, and reducing gluconeogenesis in the liver. Second, in skeletal muscle, adiponectin activates the expression of involved molecules in fatty-acid transport, such as uncoupling protein 2.
during energy dissipation and CD36, acyl-coenzyme A oxidase involved in combustion of fatty acid\(^53\). These changes result in decreased triglyceride content in skeletal muscle. Third, adiponectin activates fatty-acid combustion and energy consumption through peroxisome proliferator-activated receptor-\(\alpha\) activation\(^54\), which leads to decreased triglyceride content in the liver and skeletal muscle, and thus increased insulin sensitivity. An animal study carried out by Maeda et al.\(^55\) showed that adiponectin/ACRP30-knockout mice delayed clearance of free fatty acid in plasma, lower levels of fatty-acid transport protein 1 messenger ribonucleic acid in muscle, higher levels of tumor necrosis factor-alpha messenger ribonucleic acid in adipose tissue and high plasma tumor necrosis factor-alpha concentrations, resulting in severe diet-induced insulin resistance. Iwabu et al.\(^56\) found that decreased levels of adiponectin and AdipoR1 in obesity could have causal roles in mitochondrial dysfunction and insulin resistance seen in Muscle-RIKO mice. Furthermore, Okada-Iwabu et al.\(^57\) found that AdipoR agonist ameliorated diabetes of obese rodent model db/db mice, and concluded that orally active AdipoR agonists are a promising therapeutic approach for the treatment of insulin resistance and type 2 diabetes.

Some studies, however, have not found an association between adiponectin levels and prediabetes\(^47\).\(^49\). Some studies have not found lower adiponectin levels in prediabetes compared with healthy controls\(^21\).\(^22\).\(^27\). Furthermore, adiponectin is expressed in different multimer complexes, and the high-molecular weight (HMW) multimer is the most potent biological form, which is decreased in patients with prediabetes compared with normal controls\(^17\).\(^23\).

The present results showed significant heterogeneity among the studies \((I^2 = 89.9\%, \ P < 0.001; \text{Figure } 2)\). There are two sources of heterogeneity: one is within-study variability, which means a difference within a study of estimating the same effect size; the other is between-study variability, which means differences among studies in estimating effect size. In the present study, the meta-analysis showed that there was large heterogeneity among studies. Subsequent subgroup analysis stratified by eight potential sources was carried out (Table 2). We found significant differences in circulating adiponectin levels between prediabetes patients and healthy controls in the subgroup analysis stratified by HOMA-IR ratio, age, sample size, blood sample and quality score. No significant difference was observed in circulating adiponectin levels between prediabetes

![Figure 5](https://onlinelibrary.wiley.com/journal/jdi)

**Figure 5** | Subgroup meta-analysis for adiponectin levels in prediabetes patients and healthy controls by age. Calculation based on random effects model. Results are expressed as weighted mean difference (WMD) and 95% confidence intervals (95% CI). The total WMD in the included studies with age is significant and it showed a trend of a direct correlation with age.
patients and healthy controls only in the USA. In addition, when HOMA-IR ratio and age were used in the subgroup analysis, it showed the accepted fact that HOMA-IR ratio and age are directly related to the level of adiponectin. To further investigate the source of heterogeneity, we carried out a meta-regression, and found that geographic region might contribute to the overall heterogeneity (Asia $P = 0.001$). However, no significant contribution was found in HOMA-IR ratio, age, BMI and sample size. To conclude, the geographic region might be the main source of heterogeneity.

To the best of our knowledge, this is the most comprehensive meta-analysis to estimate the association between adiponectin levels and prediabetes. Adequate numbers of cases and controls were included from all available publications concerned with circulating adiponectin levels and prediabetes, which greatly increased the statistical power of the analysis and provided enough evidence for us to make a correct conclusion. Furthermore, participants in 13 included studies were mentioned without treating medications that could affect the level of circulating adiponectin, whereas the records of drug usage were not mentioned for the other participants in eight included studies. It is known to all that prediabetes patients can be cured by exercise and healthy diet, so there is no need to take medications. Thus, medication had little impact on the adiponectin level, and it strengthened the reliability of the present results. Furthermore, in order to eliminate the influence of sex, subgroup analysis of sex was carried out, which showed that the decrease of adiponectin levels between prediabetes patients and healthy controls in female participants was more significant than that in male participants. The results of mean adiponectin levels in female and male participants, respectively, were also consistent with the fact that serum adiponectin is higher in females than males. In addition, sensitivity analysis showed that no single study affected the pooled WMD qualitatively. Furthermore, cumulative meta-analysis showed that no substantive change had occurred in pooled WMD after the study was published in 2007, suggesting the stability of the association between low adiponectin levels and prediabetes patients. Furthermore, no publication bias was detected in the present meta-analysis, which showed that the pooled results of our study should be reliable. To summarize, these results confirm the strengths of our meta-analysis.
The possible limitations of the present study should also be considered. First, 15 case–control studies and three cohort studies, but no randomized controlled trial included in the meta-analysis, might substantially weaken the quality of this study. Second, our results were concluded without adjusting the confounding factors, such as smoking status, alcoholic consumption, environmental factors and other diet lifestyle factors. Third, this meta-analysis included small sample size studies and the backgrounds of patients varied, which would result in low statistical power and inconsistent results among studies. Finally, insufficient data were available. The influence of visceral adiposity could not be evaluated, as waist circumference or waist-to-hip ratio was not available in the majority of studies. Insufficient data of HMW adiponectin limited the estimate of the association between HMW adiponectin levels and prediabetes. Despite these limitations, the present findings could provide useful information on the diseases, and might help impose a stricter follow up and possibly an early treatment initiation, thus preventing the progression to diabetes. Furthermore, our findings might motivate more randomized controlled trials to be carried out to obtain better understanding of causal relationships between the level of adiponectin and prediabetes.

In conclusion, based on the findings of existing studies, adiponectin levels in prediabetes patients are lower than that of healthy controls.}

### Table 3 | Univariate meta-regression of the included studies of adiponectin and prediabetes

| Covariates       | No. studies | Coefficient | Standard error | t   | P     | 95% Confidence interval |
|------------------|-------------|-------------|----------------|-----|-------|-------------------------|
| Region           |             |             |                |     |       |                         |
| Asia             | 14          | 1.912       | 0.490          | 3.90| 0.001 | 0.881, 2.942             |
| Europe           | 5           | 1.392       | 0.672          | 2.07| 0.053 | –0.020, 2.803            |
| America          | 2           | –           |                |     |       |                         |
| Sample size      | 21          | 0.000025    | 0.000029       | 0.86| 0.398 | –0.000003, 0.000008      |
| Age              | 20          | –0.022      | 0.026          | –0.87| 0.393 | –0.076, 0.031            |
| HOMA-IR ratio    | 12          | –1.145      | 0.573          | –2.00| 0.074 | –2.421, 0.131            |
| BMI              | 19          | –0.066      | 0.075          | –0.88| 0.391 | –0.225, 0.093            |

BMI, body mass index; HOMA-IR ratio, mean values of homeostatic model assessment of insulin resistance in prediabetes subjects to controls in a single study.
healthy controls, showing that adiponectin decreases before the onset of diabetes. This result should be taken with caution because of the substantial heterogeneity among existing studies.

There is a need for more well-designed, high-quality studies to clarify the possible causal relationship between adiponectin levels and prediabetes patients. In addition, further investigation is required to clarify whether HMW adiponectin levels are also suppressed in prediabetes.

ACKNOWLEDGMENTS

Our study was supported by the National Training Programs of Innovation and Entrepreneurship for Undergraduates (No. 201312121002). The authors declare no conflict of interest.

REFERENCES

1. Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013; 37(Suppl 3): S294.
2. Burson R, Moran K. Prediabetes. Home Healthc Nurse 2014; 32: 317.
3. Ferrannini E. Definition of intervention points in prediabetes. Lancet Diabetes Endocrinol 2014; 2: 667–675.
4. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005; 118: 939–947.
5. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334: 299.
6. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013; 17: 185–196.
7. Caselli C, D’Amico A, Cabiati M, et al. Back to the heart: the protective role of adiponectin. Pharmacol Res 2014; 82c: 9–20.
8. Mente A, Meyre D, Lanktree MB, et al. Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. PLoS One 2013; 8: e66808.
9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
10. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014; 14: 45.
11. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
12. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157–162.
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
15. Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002; 31: 88–95.

16. Behre CJ, Brohann G, Hulte J, et al. Serum adiponectin in a population sample of 64-year-old women in relation to glucose tolerance, family history of diabetes, autoimmunity, insulin sensitivity, C-peptide, and inflammation. Metabolism 2006; 55: 188–194.

17. Jee SH, Ahn CW, Park JS, et al. Serum adiponectin and type 2 diabetes: a 6-year follow-up cohort study. Diabetes Metab J 2013; 37: 252–261.

18. Kassi E, Dalmat M, Hroussalas G, et al. Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGGT. Maturitas 2010; 67: 72–77.

19. Ko GT, So WY, Tong P, et al. Hypoadiponectinaemia enhances waist circumference as a predictor of glucose intolerance and clustering of risk factors in Chinese men. Diabetes Metab 2010; 36: 192–197.

20. Liu Y, Li J, Zhang Z, et al. Endocrinological analysis of endothelium-dependent vasodilation in middle-aged patients with impaired glucose tolerance during prediabetes mellitus. Exp Ther Med 2014; 7: 697–702.

21. Matsuhasa M, Yamasaki Y, Emoto M, et al. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007; 77: 151–154.

22. Osei K, Gaillard T, Schuster D. Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes. Obes Res 2005; 13: 179–185.

23. Ozeki N, Hara K, Yatsuka C, et al. Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. Metabolism 2009; 58: 1470–1476.

24. Pscherer S, Heemann U, Frank H. Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010; 33: 914–919.

25. Rhee SY, Kwon MK, Park BJ, et al. Differences in insulin sensitivity and secretory capacity based on OGGT in subjects with impaired glucose regulation. Korean J Intern Med 2007; 22: 270–274.

26. Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 2003; 26: 2383–2388.

27. Snehalatha C, Mukesh B, Simon M, et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226–3229.

28. Stefan N, Stumvoll M, Voizarova B, et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26: 3315–3319.

29. Tonjes A, Fasshauer M, Kratzsch J, et al. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010; 5: e13911.

30. Upadhaya S, Kadamode V, Mahammed R, et al. Adiponectin and IL-6: mediators of inflammation in progression of healthy to type 2 diabetes in Indian population. Adipocyte 2014; 3: 39–45.

31. Webb DR, Kunti K, Chatterjee S, et al. Adipocytokine associations with insulin resistance in British South Asians. J Diabetes Res 2013; 2013: 561016.

32. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935.

33. Wolfson N, Gavish D, Matas Z, et al. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp Diabetes Res 2012; 2012: 250621.

34. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179–188.

35. Dibello JR, Baylin A, Viali S, et al. Adiponectin and type 2 diabetes in Samoan adults. Am J Hum Biol 2009; 21: 389–391.

36. Yamamoto S, Matsushita Y, Nakagawa T, et al. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes 2014; 4: e130.

37. Knobler H, Benderly M, Boyko V, et al. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J Endocrinol 2006; 154: 87–92.

38. Jalovaara K, Santaniemi M, Timonen M, et al. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism 2008; 57: 1130–1134.

39. Bonneau GA, Pedrozo WR, Berg G. Adiponectin and waist circumference as predictors of insulin-resistance in women. Diabetes Metab Syndr 2014; 8: 3–7.

40. Pauer J, Fek A, Buday B, et al. [Metabolic alteration in healthy men with first degree type 2 diabetic relatives]. Orv Hetil 2013; 154: 178–186.

41. Obata Y, Yamaoda Y, Kyo M, et al. Serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes. J Diabetes Investig 2013; 4: 475–482.

42. Li CJ, Zhang JY, Yu DM, et al. Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr 2014; 6: 41.

43. Stefan N, Sun Q, Fritsche A, et al. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and
cross-sectional phenotyping studies. *PLoS One* 2014; 9: e92238.

44. Kim SY, Lee SJ, Park HK, et al. Adiponectin is associated with impaired fasting glucose in the non-diabetic population. *Epidemiol Health* 2011; 33: e2011007.

45. Daimon M, Oizumi T, Kato T. Decreased serum levels of adiponectin as a risk for development of type 2 diabetes, and impaired glucose tolerance as a risk for stroke—the Funagata study. *Nihon Rinsho* 2012; 70(Suppl 3): 256–259.

46. Luo R, Li X, Jiang R, et al. Serum concentrations of resistin and adiponectin and their relationship to insulin resistance in subjects with impaired glucose tolerance. *J Int Med Res* 2012; 40: 621–630.

47. Hammana I, Malet A, Costa M, et al. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. *Diabetes Metab* 2007; 33: 213–219.

48. Gao H, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. *Diabetes* 2013; 62: 1338–1344.

49. Yaghootkar H, Lamina C, Scott RA, et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. *Diabetes* 2013; 62: 3589–3598.

50. Yadav A, Kataria MA, Saini V, et al. Role of leptin and adiponectin in insulin resistance. *Clin Chim Acta* 2013; 417: 80–84.

51. Yamauchi T, Kannon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 2003; 423: 762–769.

52. Yamauchi T, Kannon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 2002; 8: 1288–1295.

53. Xu A, Yin S, Wong L, et al. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. *Endocrinology* 2004; 145: 487–494.

54. Zhu M, Miura J, Lu LX, et al. Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. *Exp Gerontol* 2004; 39: 1049–1059.

55. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med* 2002; 8: 731–737.

56. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. *Nature* 2010; 464: 1313–1319.

57. Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. *Nature* 2013; 503: 493–499.

*SUPPORTING INFORMATION*

Additional Supporting Information may be found in the online version of this article:

**Figure S1** | Subgroup meta-analysis for adiponectin levels in prediabetes patients and healthy controls by measurement method for adiponectin.

**Figure S2** | Subgroup meta-analysis for adiponectin levels in prediabetes patients and healthy controls by blood sample.

**Figure S3** | Subgroup meta-analysis for adiponectin levels in prediabetes patients and healthy controls by sample size.

**Figure S4** | Sensitivity analysis for adiponectin levels in prediabetes patients and healthy controls in included studies.